艾灸足三里丰隆对高脂血症模型大鼠干预及临床验证研究
摘要
目的：
我们在挖掘祖国传统中医理论的基础上,经过归纳与整理,在“脾胃为后天之本”,“脾主运化”,“脾为生痰之源”等中医传统经典理论的指导下,不断深化对高脂血症病因病机的认识。我们认为：升高的血脂属于中医无形之痰的范畴,病变主要在脾胃二脏,虚以脾虚为主,实以痰滞为标。
在本次研究中,先观察艾灸足三里、丰隆穴、足三里合丰隆穴对高脂血症模型大鼠血脂的影响,再将动物实验得的成果运用到临床中,观察艾灸足三里、丰隆穴、足三里合丰隆穴在动物研究与临床研究是否有差别。
方法：
本论文第一部分是关于高脂血症的文献研究,阐述了现代医学和祖国医学对高脂血症的认识、治疗、以及临床上遇到的问题,重点说明了针灸在这方面的优势。在第二部分动物研究中,SD大鼠60只,雌雄各半,普通饲料喂养2天后,根据体重按随机数字表,将大鼠随机分为空白对照组8只,模型对照组11只,足三里组13只,丰隆组14只、足三里合丰隆组14只。以高脂饲料喂养模型对照组、足三里组、丰隆组、足三里合丰隆组,四周后,检测各组的血清学指标,以确定造模成功,再在接下来的8周里,都用普通饲料喂养,治疗组给予艾灸相关穴位,模型对照组只抓取动物,而不进行治疗,以观察艾灸足三里、艾灸丰隆、艾灸足三里合丰隆对高脂血症模型大鼠血脂、血液流变学的影响。在第三部分,先选取75名高脂血症患者,以随机分组的方式分到足三里组25例、丰隆组23例、足三里合丰隆组27例,后共脱落9例,观察患者的血脂指标、体型、临床症状的变化。
结果：
1.模型大鼠血脂及AI水平比较：在艾灸治疗8周后,与模型组比较,足三里组、丰隆组、足三里合丰隆组血清TG、TC、LDL-C水平、AI指数都显著降低,差异具有显著性(P<0.01)；HDL-C水平都显著升高。其中足三里组、足三里合丰隆组在降TC方面更具有优势；丰隆组、足三里合丰隆组在降LDL-C方面更具有优势。
2.血液流变学比较：与模型组比较,足三里组、丰隆组、足三里合丰隆组的高切变率、低切变率、血浆粘度、红细胞压积、红细胞电泳时间、红细胞聚集指数都显著下降,差异具有显著性。
3.临床患者血脂水平比较：足三里组、丰隆组、足三里和丰隆组皆可降血脂,其中足三里合丰隆组更有效。
4.临床患者体型比较：治疗后三组患者体型无明显改变。
5.临床患者症状积分比较：足三里组、丰隆组、足三里和丰隆组皆可有效降低高脂血症患者的症状积分,其中足三里合丰隆组更有效。
结论：
1.艾灸足三里、丰隆穴、足三里合丰隆穴,可以有效地降低高脂血症模型大鼠的血清TC、TG、LDL-C、AI指数,升高HDL-C。
2.艾灸足三里、足三里合丰隆穴在降低高脂血症模型大鼠血清TC明显,艾灸丰隆、足三里合丰隆穴在降低高脂血症模型大鼠血清LDL-C明显。
3.艾灸足三里、丰隆穴、足三里合丰隆穴,可以有效地降低高脂血症模型大鼠血液流变学各项指标。
4.艾灸足三里、丰隆穴、足三里合丰隆穴可有效治疗患者的高脂血症,而且两穴合用效果更好。
5.艾灸足三里、丰隆穴、足三里合丰隆穴可有效降低高脂血症患者的临床积分、改善患者的临床症状,而且两穴合用效果更好,但改善患者体型作用不明显。
6.为“脾主运化”“脾胃为后天之本”“脾为生痰之源”的中医基础理论提供了一定的实验室和临床依据。
Objective
Mining the basis of the traditional Chinese medicine theory, after induction and consolidation, under the guidance of the classical theory that including" the stomach and the spleen are acquired","spleen governs the transportation","the spleen is the source of phlegm", and constantly deepen the understanding of the etiology and pathogenesis of hyperlipidemia. We believe that:elevated blood lipids belong to the scope of TCM invisible sputum, lesions in the spleen and stomach two dirty,virtual Spleen-based,real phlegm stagnation as the standard.
In this study, the first observation of the moxibustion Zusanli point, the moxibustion Fenglong point,the moxibustion Zusanli together Fenglong point on serum lipids of hyperlipidemic model,then the animal experiments of the results of use in the clinical,observation Observe whether the animal studies and clinical research makes a difference.
Methods
The first part of this paper is a literature study on hyperlipidemia on the understanding and treatment of modern medicine and the tradition medicine hyperlipidemia, and clinical problems encountered, highlighting the advantages of acupuncture in this respect.In the second part of the animal studies, SD rats60, male and female in half, fed with normal diet after2days according to body weight according to the random number table, the rats were randomly divided into the blank control group of8, the model control group of10, the Zusanli group Of13, the Fenglong of14, the Zusanli together Fenglong group of13. the High fat diet model group, the Zusanli group, the Fenglong group, Zusanli together Fenglong group, four weeks after the detection of serological markers in each group to determine the model was successful,and then in the next eight weeks,fed with normal diet, the treatment group received moxibustion related points,just crawl animal model control group without treatment, to observe moxibustion at Zusanli, moxibustion Leong, moxibustion Zusanli together Fenglong the hyperlipidemic disease model of serum lipids and hemorheology.In the third section, first select the75patients with hyperlipidemia, randomized25cases assigned to the Zusanli group, the Fenglong group of23cases, the Zusanli together Fenglong group of27patients,after shedding nine cases,observationthe patient's serum lipids, body, changes in clinical symptoms.
Results
1.A rat model of blood lipids and AI levels:8weeks after the moxibustion treatment,compared with model group, the Zusanli group, the Fenglong group,Zusanli together Fenglong serum TG,TC and LDL-C level,AI Index significantly lower difference(P<0.01),HDL-C levels were significantly elevated.the Zusanli group and the Zusanli together Fenglong group have more advantages in lowering TC,the Fenglong group and the Zusanli together Fenglong group have more advantages in lowering LDL-C.
2.Hemorheology:Compared with the model group, the Zusanli group, the Hong Leong group,the Zusanli together Fenglong group of high shear and low shear rate,plasma viscosity,hematocrit,erythrocyte electrophoresis time, erythrocyte aggregation index were significantly decreased,the difference was significant.
3.Clinical lipid levels in patients with:the Zusanli group, the Hong Leong group, the Zusanli together Fenglong group can be lowering blood pressure,which together Hong Leong group Zusanli more effective
4.Body of clinical patients:no significant change after treatment,three groups of patients with body size.
5.clinical symptoms points:the Zusanli group, the Fenglong group, the Zusanli together Fenglong group can be effective to reduce the symptom score of patients with hyperlipidemia, in which the Zusanli together Fenglong group more effective.
Conclusion
1.the moxibustion Zusanli point,Fenglong point,Zusanli together Fenglong point,and hyperlipidemia model rats can effectively reduce serum TC, TG and LDL-C,AI index,elevated HDL-C.
2.Moxibustion at Zusanli point, Zusanli together Fenglong point significantly reduce hyperlipidemia model serum TC, the moxibustion Fenglong, Zusanli together Fenglong point in reducing hyperlipidemia model of serum LDL-C obvious.
3.The moxibustion Fenglong point,Zusanli together Fenglong point,can effectively reduce the hyperlipidemia model rats hemorheological parameters.
4. Moxibustion Zusanli point,Fenglong point,Zusanli together Fenglong point can be effective in treating patients with hyperlipidemia, and the combination of the two points better.
5.Moxibustion Zusanli point,Fenglong point,Zusanli together Fenglong point can effectively reduce the clinical integration of the patients with hyperlipidemia, to improve the patient's clinical symptoms, and the combination of the two points better, but to improve the patients body is not obvious.
6.The basic theory of Chinese medicine as the"the stomach and the spleen are acquired","spleen governs the transportation","the spleen is the source of phlegm" certain laboratory and clinical evidence.
我们在挖掘祖国传统中医理论的基础上,经过归纳与整理,在“脾胃为后天之本”,“脾主运化”,“脾为生痰之源”等中医传统经典理论的指导下,不断深化对高脂血症病因病机的认识。我们认为：升高的血脂属于中医无形之痰的范畴,病变主要在脾胃二脏,虚以脾虚为主,实以痰滞为标。
在本次研究中,先观察艾灸足三里、丰隆穴、足三里合丰隆穴对高脂血症模型大鼠血脂的影响,再将动物实验得的成果运用到临床中,观察艾灸足三里、丰隆穴、足三里合丰隆穴在动物研究与临床研究是否有差别。
方法：
本论文第一部分是关于高脂血症的文献研究,阐述了现代医学和祖国医学对高脂血症的认识、治疗、以及临床上遇到的问题,重点说明了针灸在这方面的优势。在第二部分动物研究中,SD大鼠60只,雌雄各半,普通饲料喂养2天后,根据体重按随机数字表,将大鼠随机分为空白对照组8只,模型对照组11只,足三里组13只,丰隆组14只、足三里合丰隆组14只。以高脂饲料喂养模型对照组、足三里组、丰隆组、足三里合丰隆组,四周后,检测各组的血清学指标,以确定造模成功,再在接下来的8周里,都用普通饲料喂养,治疗组给予艾灸相关穴位,模型对照组只抓取动物,而不进行治疗,以观察艾灸足三里、艾灸丰隆、艾灸足三里合丰隆对高脂血症模型大鼠血脂、血液流变学的影响。在第三部分,先选取75名高脂血症患者,以随机分组的方式分到足三里组25例、丰隆组23例、足三里合丰隆组27例,后共脱落9例,观察患者的血脂指标、体型、临床症状的变化。
结果：
1.模型大鼠血脂及AI水平比较：在艾灸治疗8周后,与模型组比较,足三里组、丰隆组、足三里合丰隆组血清TG、TC、LDL-C水平、AI指数都显著降低,差异具有显著性(P<0.01)；HDL-C水平都显著升高。其中足三里组、足三里合丰隆组在降TC方面更具有优势；丰隆组、足三里合丰隆组在降LDL-C方面更具有优势。
2.血液流变学比较：与模型组比较,足三里组、丰隆组、足三里合丰隆组的高切变率、低切变率、血浆粘度、红细胞压积、红细胞电泳时间、红细胞聚集指数都显著下降,差异具有显著性。
3.临床患者血脂水平比较：足三里组、丰隆组、足三里和丰隆组皆可降血脂,其中足三里合丰隆组更有效。
4.临床患者体型比较：治疗后三组患者体型无明显改变。
5.临床患者症状积分比较：足三里组、丰隆组、足三里和丰隆组皆可有效降低高脂血症患者的症状积分,其中足三里合丰隆组更有效。
结论：
1.艾灸足三里、丰隆穴、足三里合丰隆穴,可以有效地降低高脂血症模型大鼠的血清TC、TG、LDL-C、AI指数,升高HDL-C。
2.艾灸足三里、足三里合丰隆穴在降低高脂血症模型大鼠血清TC明显,艾灸丰隆、足三里合丰隆穴在降低高脂血症模型大鼠血清LDL-C明显。
3.艾灸足三里、丰隆穴、足三里合丰隆穴,可以有效地降低高脂血症模型大鼠血液流变学各项指标。
4.艾灸足三里、丰隆穴、足三里合丰隆穴可有效治疗患者的高脂血症,而且两穴合用效果更好。
5.艾灸足三里、丰隆穴、足三里合丰隆穴可有效降低高脂血症患者的临床积分、改善患者的临床症状,而且两穴合用效果更好,但改善患者体型作用不明显。
6.为“脾主运化”“脾胃为后天之本”“脾为生痰之源”的中医基础理论提供了一定的实验室和临床依据。
Objective
Mining the basis of the traditional Chinese medicine theory, after induction and consolidation, under the guidance of the classical theory that including" the stomach and the spleen are acquired","spleen governs the transportation","the spleen is the source of phlegm", and constantly deepen the understanding of the etiology and pathogenesis of hyperlipidemia. We believe that:elevated blood lipids belong to the scope of TCM invisible sputum, lesions in the spleen and stomach two dirty,virtual Spleen-based,real phlegm stagnation as the standard.
In this study, the first observation of the moxibustion Zusanli point, the moxibustion Fenglong point,the moxibustion Zusanli together Fenglong point on serum lipids of hyperlipidemic model,then the animal experiments of the results of use in the clinical,observation Observe whether the animal studies and clinical research makes a difference.
Methods
The first part of this paper is a literature study on hyperlipidemia on the understanding and treatment of modern medicine and the tradition medicine hyperlipidemia, and clinical problems encountered, highlighting the advantages of acupuncture in this respect.In the second part of the animal studies, SD rats60, male and female in half, fed with normal diet after2days according to body weight according to the random number table, the rats were randomly divided into the blank control group of8, the model control group of10, the Zusanli group Of13, the Fenglong of14, the Zusanli together Fenglong group of13. the High fat diet model group, the Zusanli group, the Fenglong group, Zusanli together Fenglong group, four weeks after the detection of serological markers in each group to determine the model was successful,and then in the next eight weeks,fed with normal diet, the treatment group received moxibustion related points,just crawl animal model control group without treatment, to observe moxibustion at Zusanli, moxibustion Leong, moxibustion Zusanli together Fenglong the hyperlipidemic disease model of serum lipids and hemorheology.In the third section, first select the75patients with hyperlipidemia, randomized25cases assigned to the Zusanli group, the Fenglong group of23cases, the Zusanli together Fenglong group of27patients,after shedding nine cases,observationthe patient's serum lipids, body, changes in clinical symptoms.
Results
1.A rat model of blood lipids and AI levels:8weeks after the moxibustion treatment,compared with model group, the Zusanli group, the Fenglong group,Zusanli together Fenglong serum TG,TC and LDL-C level,AI Index significantly lower difference(P<0.01),HDL-C levels were significantly elevated.the Zusanli group and the Zusanli together Fenglong group have more advantages in lowering TC,the Fenglong group and the Zusanli together Fenglong group have more advantages in lowering LDL-C.
2.Hemorheology:Compared with the model group, the Zusanli group, the Hong Leong group,the Zusanli together Fenglong group of high shear and low shear rate,plasma viscosity,hematocrit,erythrocyte electrophoresis time, erythrocyte aggregation index were significantly decreased,the difference was significant.
3.Clinical lipid levels in patients with:the Zusanli group, the Hong Leong group, the Zusanli together Fenglong group can be lowering blood pressure,which together Hong Leong group Zusanli more effective
4.Body of clinical patients:no significant change after treatment,three groups of patients with body size.
5.clinical symptoms points:the Zusanli group, the Fenglong group, the Zusanli together Fenglong group can be effective to reduce the symptom score of patients with hyperlipidemia, in which the Zusanli together Fenglong group more effective.
Conclusion
1.the moxibustion Zusanli point,Fenglong point,Zusanli together Fenglong point,and hyperlipidemia model rats can effectively reduce serum TC, TG and LDL-C,AI index,elevated HDL-C.
2.Moxibustion at Zusanli point, Zusanli together Fenglong point significantly reduce hyperlipidemia model serum TC, the moxibustion Fenglong, Zusanli together Fenglong point in reducing hyperlipidemia model of serum LDL-C obvious.
3.The moxibustion Fenglong point,Zusanli together Fenglong point,can effectively reduce the hyperlipidemia model rats hemorheological parameters.
4. Moxibustion Zusanli point,Fenglong point,Zusanli together Fenglong point can be effective in treating patients with hyperlipidemia, and the combination of the two points better.
5.Moxibustion Zusanli point,Fenglong point,Zusanli together Fenglong point can effectively reduce the clinical integration of the patients with hyperlipidemia, to improve the patient's clinical symptoms, and the combination of the two points better, but to improve the patients body is not obvious.
6.The basic theory of Chinese medicine as the"the stomach and the spleen are acquired","spleen governs the transportation","the spleen is the source of phlegm" certain laboratory and clinical evidence.
引文
[1]郭美珠,肖燕倩,孙丽英,等.中医药治疗高脂血症实验研究的进展[J].中医药信息,2003,20(6)：44.
[2]吴兴斌.浅析常用调脂药物应用状况[J].临床用药,2008,5(7)：660-661.
[3]庞剑,杜文斌,周学文.高脂血症的中西医研究集析[J].中医药学刊,2003,21(12)：2124
[4]Dobiasova M, Frohieh J. The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio the lipoprotein particle size and The cholesterol esterif ication rate, changes during lipanor therapy [J]. Vnitr Lek,2000,46 (3):152-156.
[5]锦海,翟沙湖.甘油三酯/高密度脂蛋白胆固醇比值与急性冠脉综合征患者冠脉病变的关系[J].中国医药导刊,2002,4(4)：263-264.
[6]Weinberger J. Prevention of ischemic stroke [J]. Curr Card iol Rep,2002,4(2):164-171.
[7]刘晓宁,孙莉,李昭晖,等.心肌梗死和脑梗死病人载脂蛋白a五核昔酸重复序列基因多态性及血浆脂蛋白a水平的关系[J].中华医学杂志,2000,82(20)：1396-139.
[8]杨智敏.高脂血症的中医药治疗研究初探[J].现代医药卫生,2005,21(23)：3241-3242.
[9]于克娇.中医对高脂血症的认识和治疗现状[J].中国航天工业医药,2000,2(4)：79-80.
[10]周美芳.从痰瘀论治高脂血症88例临床观察[J].贵阳中医学院学报,2005,27(1)：43.
[11]李文彪,刘星,张蕴慧.高脂血症病因与发病[J].山东中医药大学学报,1999,23(5)：336-337.
[12]占新平.高脂血症中医辨证治疗的体会[J].邯郸医学高等专科学校学报,2005,8(1)：46-47.
[13]龚一萍.高脂血症的中医病因病机探讨[J].浙江中医学院学报,2000,24(2)：23-24.
[14]钱卫东,庄德成,朱学云,等.高脂血症中医病因病机探讨[J].湖北中医杂志,2001,23(11)：5-6.
[15]张琦,江泳,陈建杉.苓桂术甘汤对高脂血症大鼠血流变学影响的实验研究[J].成都中医药大学学报,2003,26(3)：11-14.
[16]范英昌,陆一竹,张艳军,等.调肝导浊中药对大鼠实验性高脂血症及主动脉平滑肌细胞增殖影响的实验研究[J].中国老年学杂志,2002,24(22)：127-129.
[17]杨大男,杨代勇,张惠芹.逍遥丸治疗高脂血症84例[J].陕西中医,1995,16(3)：109-110.
[18]吴元洁,王正,王玉凤.“痰浊”与高脂血症相关性初探[J].中医药临床杂志,2004,16(3)：201-202.
[19]从华伟,王忠玉,王玉凤.从肝脾论治高脂血症[J].中国中医药,2005,3(1)：53.
[20]尹柱汉, 陈冰.从脏腑虚实论治高脂血症[J].时珍国医国药,2001,12(6)：551.
[21]昌炳如.高脂血症的病因病机与治疗探讨[J].中医研究,2005,18(8)：3-5.
[22]浦斌红.浅谈高脂血症的中医药治疗方法[J].甘肃中医,2000,13(5)：4-6.
[23]陈志惠.高脂血症中医证治研究概述[J].福建中医药,1993,24(4)：56-59.
[24]吴卫红.调脂饮治疗高脂血症60例[J].辽宁中医杂志,2003,30(4)：279.
[25]于文涛,李进龙,田元祥,等.杨牧祥教授从痰瘀论治高脂血症的经验[J].河北中医,2006,28(3)：165-166.
[26]杜国玲.中医辨治高脂血症之经验[J].中华综合医学杂志,2005,6(7)：582.
[27]朱巧,张颖.高脂血症的中医治疗探讨[J].中国中医急症,2005,14(9)：834.
[28]岳增辉,严洁,常小荣.中医药防治高脂血症的研究进展[J].湖南中医学院学报,2005,25(2)：63-64.
[29]任合秀.试论高脂血症中医辨证思路[J].武警医学院学报,2002,11(2)：89.
[30]Grundy SM, et al. (2001). Executive summary of the third report of the National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Pane[J]. JAMA,285 (19): 2486-249.
[31]陈撷珠.实用内科学[M],第10版.北京：人民卫生出版社,1998,877-890.
[32]冯学冠,邱辅佑,黄慈花,等.379例高脂血症血脂及载脂蛋白水平的分析[J].海南医学,1994,5(1)：30-32.
[33]Wood DA. Cholesterol lowering does have a role in secondary Prevention[J].Br Heart,1995,73(1):4-5.
[34]王振杰,武阳丰,周北凡.高脂血症的膳食治疗[J].中国慢性病预防与控制,2003,11(6)：286-289.
[35]杨卫国,金莉子.膳食结构的变化对高脂血症患者血脂水平的影响[J].广西预防医学,2004,10(3)：151-153.
[36]陈玉,陈豪东.高脂血症与膳食及生活习惯的关系[J].扬州大学烹饪学报,2003,12(3)：16-18.
[37]李蓉琼,方荣华,任皓.高脂血症的非药物治疗[J].现代预防医学,2005,32(4)：324-326.
[38]Wilund K. R., Colvin PL., phares D., et al. The effect of endurance exercise training on Plasma lipoprotein Al and liPoProtein Al:All concentrations in sedentary adults[J]. Metabolism,2002,51(8):1053-1060.
[39]Sunami Y., Motoyama M., Kinoshita F., et al. Effects of low-density aerobic training on the high-density lipoprote in Cholesterol concentration in healthy elderly subjects[J]. Metabolism,1999,48(8):984-988.
[40]Kraus WE, Houmard JA, Duseha BD, et al. Effects of the amout and intensity of low intensity of exercise on Plasma lipoproteins[J]. NEngl J Med, 2002,347(19):1552-1554.
[41]Tanaka A. Diet and exercise therapy of hyperliPidemia based onevidences[J]. Nippon Rimho,2002,60(5):941-947.
[42]Prabhakaran B, Dowling EA, Branch JD, et al. Effect of 14 weeks of resistancetraining on lipid profile and body fat Percent age in premenopausal women[J]. Br J Sports Med, 1999,33(3):190-195.
[43]Halle M., Berg A., Konig D., et al. Differences in the composition of low density lipoprotein subfraction Particles between Sedentary and trained hypercholesterolemic men[J]. Metabolism,1997,46(2):186-191.
[44]Huang LP, Lu X, Lin S. Exercise of hyperlipidemia[J]. Modern Rehabilitation,2001, 5(3):10-11.
[45]郑晓辉,黄可青,佘白容,等.他汀类药物治疗高血脂的研究进展[J]. 中国误诊学杂志,2008,8(17)：4043-4044.
[46]Kong SX, Crawford SY, Gandhi SK, Seeger JD, et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of Patients with hypercholesterolemia:ameta-analysis of chlinical trials[J].Clin Ther, 1997,19(4):778-797.
[37]Downs JR, Clearfield M, Weis S, Whitney E, et al. Primary Prevention of cute coronary vents with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis prevention tudy[J]. JAMA, 1998,279(20):1615-1622.
[48]Willerson JT. Effect of pravastatin on coronary events after myocardial infarction in Patients with average cholesterol levels[J]. Circulation,1996,94(12):3054.
[49]Prevention of cardiovascular events and death with pravatatin in Patients with coronary heart disease and abroad range of initial cholesterol levels. The Long-Term ntervention with Pravastatin in Ischaemic Disease(LIPID)Study Group[J].N Eng J Med, 1998,339(19):1349-1357.
[50]Scandinavian Simvastatin Survival Study Group. Randomised trial of Cholesterol lowering in 4444 Patients with coronary heart disease:The Scandinavian Simvastatin survival study(4S) [J].Lancet,1994,344(8934):1383-1389.
[51]中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-409.
[52]陈撷珠.他汀类调脂药物[J].中国处方药,2004,27(11)：10-14.
[53]杨涛,黄斌,赵桂叶,等.氟伐他汀联合非诺贝特治疗混合性高脂血症疗效观察[J].中国实用医药,2008,3(25)：18-19.
[54]缪素琼.较大剂量阿托伐他汀钙治疗38例老年混合型高血脂症临床疗效观察[J].重庆医学,2008,37(16)：1832-1834.
[55]陆宗良.规范他汀类药物的应用[J].中国医学论坛报,2007,31(8)：14.
[56]胡大一,马长生.心脏病学实践--规范化治疗[J].北京：人民卫生出版社,2006,374.
[57]Cabrero A, Alegret M, Sanehez RM et al. Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of dipocytes[J]. Diabetes,2001,50(8):1883-1890.
[58]Marx N, Sukhova GK, Collins T et al. PPAR alpha activators inhibit cytokine-induced vascular cell adhesion Molecule-1 expression in human endothelial Cells[J]. Circulation,1999,99(24):3125-3131.
[59]Staels B, Koenig W, Habib A et al. Activation of human aortic smooth muscle cells is inhibited by PPARalpha but not by PPAR—gamma activators[J]. Nature, 1998,393(6687):790-792.
[60]赵水平,吴洁.非诺贝特对高脂血症兔血清及脂肪细胞分泌肿瘤坏死因子-α的影响[J].中国药理学通报,2005,21(2)：157-161.
[61]Rubins HB, Robins SJ, Collins D, et al, Gemfibrozil for the secondary Prevention of coronary heart disease in men with low levels of high—density lipoprotein cholesterol.Veterans AFairs High—Density Lipoprotein Cholesterol Intervention Trial Study GrouP[J].N Engl Med,1999,341(6):410—418.
[62]The BIP Study Group. Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Pations with Coronary Artery Disease[J].Cireulation,2000 Jul4, 102(1):21-27.
[63]American Diabetes Association. Management of dyslipidemia in adults with diabetes[J]. Diabetes Care,2002,25(3):574-577.
[64]Rosenberg IH. Fish-Food to Calm the Heart[J].N Engl J Med, 2002,346(15):1102-1103.
[65]Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death[J].N Engl J Med,2002,346(15):1113-1118.
[66]GISSI-Prevenzione Investgators. Dietary supplementary with n-3polyunsarated fatty aeids and vitamin E after myocardial infarction:results of the GISSI-Prevenzione trial[J]. Lancet,1999,354(9177):447-455.
[67]Hu F, Bronner L, Willett WC, et al, Fish and Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in women[J]. JAMA,2002,287(14):1815-1821.
[68]Nordoy, A; Svensson, B; Hansen, JB. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia[J]. J-Thromb-Haemost,2003,1(4):690-697.
[69]Saku K, Zhang B, Jimi S, Bai H, Hirata K, Sasaki N, et al. High-density lipoprotein and apolipoprotein Al deficiency induced by combination therapy with probucol an bezafibrate[J].EurJClinPharmaeol,1995,48(3-4):209-215.
[70]Chiesa G, Miehelagnoli S, Cassinotti M, Gianfraneesehi G, Werba JP, Pazzueeoni F, et al. Meehanisms of high density lipoprotein reduction after probucol treatment: changes in plasma cholesterol esterification/transfer and lipase activitie[J]. Metabolism,1993,42(2):229-23.
[71]Homma Y, Kobayashi T, Yamaguchi H, Sakane H, Ozawa H, Matsuda M, et al. Decrease of plasma large, light LDL(LDL1), HDL2 and HDL3 levels with concomitant inerease of cholesteryl eater transfer protein(CETP) activity by Probueol in typeⅡ hyperlipoproteinemia[J]. Artery,1993,20(1):1-18.
[72]Sawayama,-Y, Shimizu,-C, Maeda,-N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial(FAST) [J]. J-Am-Coll-Cardiol,2002,39(4):610-616.
[73]Gagne ac, Gaudet D, Bruekert E, et al. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in pations with homozygous familial hypercholesterolemia[J]. Circulation,2002,105(21):2469-2475.
[74]华琦,师树英,王亭,等.苯氧芳酸类血脂调节药物吉非罗齐疗效观察[J].中华内科杂志,1997,36(11)：735.
[75]任景怡,陈红,罗宇.联合应用辛伐他汀和非诺贝特治疗混合性高脂血症的疗效及安全性观察[J].中华心血管病杂志,2005,33(2)：122-126.
[76]Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate(200mg/day) to simvastatin(10mg/day) in Patients with combined hyPerliPidemia and metabolic syndrome[J]. Am J cardiol,2003,91(8):956-960.
[77]Hodel C. MyoPathy and rhabdomyolysis with lipid-lowering drugs[J]. Toxicol Lett,2002,128(1-3):159-168.
[78]Snow V, Aronson MD, Hornbak ER, et al. Lipid control in the management of type 2 diabetes mellitus:a clinical practice guide line from the American College of Physicians[J]. Ann Intern Med,2004,140(8):644-649.
[79]American diabetes association. DysliPidemia management in adults with diabetes[J]. Diabetes Care.2004,27 SuPPll:568-571.
[80]Brown BG Zhao X-Q, Chain A et al. Simvastatin and niacin, antioxidant vitamin, or the combination for the Prevention of coronary disease[J]. N Engl J Med,2001,345(22):1583-1592.
[81]Jokubaitis LA. Fluvastatin in combination with other lipid lowering agents[J].Br J Clin Prcet Suppl,1996,77A:28-32.
[82]Erkelens DW, Baggen MG, Van Doormaal J J, et al. Clinical experience with Simvastatin compared with cholestyramine[J]. Drugs,1988,36 suppl 3:87-92.
[83]Durrington,-P-N,Bhatnaga,-D, Mackness,-M-I, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and Persisting hypertriglyceridaemia[J]. Heart,2001,85 (5):544-548.
[84]Tadateru T, Aggressive Lipid-Lowering Therapy for Secondary prevention in pations with Acute Coronary Syndrome:Volumetric and Echogenicity Analysis Using Intravascular Ultrasound. Presented on 68 th seientific Sessions of Japanese Circulation Society. March 2-29,2004. Tokyo, Japan Plenary Sessionl.
[85]张莉.中医药治疗高脂血症研究进展与展望[J].河北中医,2007,29(4)：376-377.
[86]宋立人.现代中药学大辞典[M].北京：人民卫生出版社,2001,790.
[87]王宇辉,周超凡.中药降脂研究进展[J].中国中药杂志,1999,24(3)：184-186.
[88]蔡永敏.最新中药药理与临床应用[M].北京：华夏出版社,1999,54-481.
[89]焦东海.大黄糖浆降脂作用的临床观察[J].中西医结合杂志,1990,10(2)：110-111.
[90]柴跃红,窦敏华,窦翠华.何首乌治疗高脂血症36例疗效观察[J].河北中医,2000,22(5)：346.
[91]梅齐建,吴仁如,肖鸣.抗栓灵含片对老年人高脂血和血液流变学的影响[J].中国生化药物杂志,2000,21(5)：452.
[92]詹丽芬,孙晋民,孙立,等.轻身降脂片对高血脂大鼠丙二醛及超氧化物歧化酶的影响[J].中国医科大学学报,2000,29(3)：341.
[93]王四旺,谢艳华,朱玲珍.平脂胶囊对鼠血脂和血粘的影响[J].第四军医大学学报,1999,20(10)：345.
[94]李春梅,刘莉.降脂通脉冲剂对实验性高脂血症大鼠血浆脂质及血粘度的影响[J].山西医科大学学报,2000,31(1)：34.
[95]张吉正,范英昌,张伯礼,等.脂肝清对高胆固醇血症家兔模型脂质代谢影响的实验研究[J].天津中医,2000,18(6)：29.
[96]左绍远.复方螺旋藻片降血糖、调血脂的实验研究[J].中国海洋药物,2000,19(6)：679.
[97]于志强.中医药治疗高脂血症六法[J].辽宁中医学院学报,2000,2(2)：119.
[98]吴同启.从肝脾论治高脂血症60例[J].陕西中医,2004,25(2)：133-134.
[99]王化锰.以痰凝为核心治疗高脂血症46例[J].辽宁中医杂志,2000,27(11)：499.
[100]刘启明.燥湿化痰、消积降脂法治疗高脂血症93例[J].中医药学报,2001,29(2)：9.
[101]姜文良,郭茂峰.中西医结合治疗高脂血症73例疗效观察[J].河南中医,2005,5(10)：64.
[102]钱卫东,朱学云.高脂血症中医辨治体会[J].江苏中医,2000,21(12)：14.
[103]王兴国,杜洪柱,刘华光.辨证分型治疗高脂血症102例观[J].实用中医药杂志,1999,15(9)：3-4.
[104]尹修海,罗永铁.辩证分型治疗高脂血症120例分析[J].湖南中医杂志,1999,15(3)：8-9.
[105]胡克武,丁俊.肝肾阴虚型高脂血症治疗的临床分析[J].辽宁中医杂志,1996,23(12)：542-543.
[106]马洪玲.逍遥散加减治疗高脂血症50例[J].山东中医杂志,2001,20(7)：402.
[107]谭元生,程丑夫,黄大香,等.脂康颗粒剂治疗肝肾阴虚夹癖型高脂血症的临床研究[J].中国中医药科技,1999,6(4)：213-214.
[108]袁俏梅,史红辉.穴位埋线治疗高脂血症34例—附普拉固治疗30例对照[J].浙江中医杂志,2002,23(6)：396.
[109]朱雅萍.电针治疗高脂血症60例[J].吉林中医药,2001,4(10)：53.
[110]赵惠.针刺辨证选穴治疗高脂血症的临床研究[J].中国初级卫生保健,2002,16(10)：54-55.
[111]任敬威.针刺足三里、内关穴治疗高脂血症45例报告[J].甘肃中医,1996,9(8)：36-37.
[112]毛豆菜,王月冬,周逸平.针刺对冠心病患者血脂血糖的影响[J].针灸临床杂志,1994,10(2)：26-27.
[113]周杰芳,冼志红.针刺对高血脂病人的血脂及血液流变学影响的临床观察[J].广西中医药,1994,17(3)：39-41.
[114]粱凤应.针灸对老年人高脂血症及高粘血症的影响[J].上海针灸杂志,1999,18(4)：10-12.
[115]张红星,张唐法,周利,等.电针丰隆穴治疗高脂血症临床研究[J].针灸临床杂志,2007,23(4)：7.
[116]李春杰,成小松,李春艳,等.针刺丰隆穴对正常和高脂血症大鼠血脂的调节作用[J].中国临床康复,2005,9(27)：86-87.
[117]王玉堂.针刺丰隆穴降血脂47例临床观察[J].中国针灸,1990,10(3)：21.
[118]陈德欣,吴洪英,王卓茹.针刺阳明经穴治疗高脂血症疗效观察[J].针灸临床杂志,2002,18(5)：49.
[119]陈瑞,梁风霞,毛红蓉.针刺从脾论治高脂血症的临床研究[J].中国中西医结合消化杂志,2003,11(3)：162-164.
[120]于连群.补脾泻胃针刺法治疗高脂血症疗效观察[J].中华现代中西医杂志,2005,3(11)：1027.
[121]唐胜修,唐萍.丰隆、足三里穴位注射治疗高脂血症的临床研究[J].广西医学杂志,2000,22(6)：1402.
[122]冷浩.高脂血症的针灸治疗临床观察[J].光明中医,2007,22(2)：33.
[123]张苹.针灸治疗高脂血症的临床资料分析[J].中外医疗,2008,14：6-7.
[124]刘红石.针刺并降脂减肥茶治疗单纯性肥胖并高脂蛋白血症20例[J].针灸临床杂志,2004,20(4)：17-18.
[125]曾奕.艾灸作用的实验研究进展[J].山东中医杂志,2005,24(3)：187-190.
[126]高耀华,王竹行,陈新黔,等.降脂药灸治疗中老年高脂血症的临床研究[J].中国针灸,2000,20(2)：77.
[127]史恒军,赵宁侠,郭瑞林,等.温和灸对健康人甲皱微循环影响的临床研究[J].成都中医药大学学报,2004,27(1)：42-43.
[128]邓柏颖,谢感共,罗本华,等.功能保健灸治疗高脂血症48例疗效观察[J].新中医,2002,34(9)：48-49.
[129]管遵惠,金建华,申晓月.子午流注灸法治疗高脂血症50例临床观察[J]. 中医杂志,1994,35(2)：108-109.
[130]吴中朝,王玲玲,刘跃光,等.艾灸对老年人血液载脂蛋白研究[J].中国针灸,1998,18(5)：261-262.
[131]李建萍,姚永年,何培达,等.艾灸治疗血脂异常患者的临床研究[J].中国针灸,2005,25(11)：825-827.
[132]张红星,张唐法,周利等.电针丰隆穴治疗高脂血症临床研究[J].针灸临床杂志,2007,23(4)：7-8.
[133]卢振初.耳压法治疗单纯性肥胖症29例的血脂和脂蛋白观察[J].南京中医学院学报,1989,(2)：40.
[134]王华.丹参穴位注射治疗高脂血症40例临床分析[J].中国针灸,1997,(8)：469.
[135]刘晓辉.当归维生素B12混合穴位注射治疗高脂血症56例[J].时珍国医国药,2001,12(4)：360.
[136]刘运珠,岁继红,宁发锦,等.穴位注射对高脂血症患者血脂的影响[J].上海针灸杂志,2007；26(2)：15-16.
[137]王倩,熊萃,等.穴位埋线治疗肥胖型高脂血症52例疗效观察[J].新中医,2005,37(6)：64-65.
[138]李兴文.He-Ne激光穴位照射治疗高脂血症疗效观察[J].中国临床医学,2000,7(3)：317.
[139]李相忠,董壮丽.超声波治疗高脂血症的实验及临床观察[J].中国循环杂志,1994;9(8)：46.
[140]王成传,郑建寅,谢宁.哈慈五行针治疗飞行人员高脂血症疗效观察[J].中华航空航天医学杂志,2001,12(4)：239-240.
[141]张丽,盛丽.磁化针治疗高脂血症的疗效观察[J].中国针灸,2002,22(5)：337-338.
[142]杨国柱,曹欣.皮内针治疗高脂血症32例临床观察[J].江苏中医药,2003,24(12)：38.
[143]包哈申,斯钦图,那顺布和,等.放血疗法治疗高脂血症的临床观察[J].针灸临床杂志,2002,18(11)：33-35.
[144]韩丽英.穴位贴敷治疗高脂血症临床观察[J].辽宁中医杂志,2003,30(6)：462
[145]杨丹红,许文波,江庆湛.穴位注射对高脂血症动物模型的降脂作用[J].针灸临床杂志,2000,16(1)：43-45.
[146]解秸萍,李晓乱,张露芬,等.针刺不同穴位对高脂血症大鼠血脂影响的实验研究[J].北京中医药大学学报,2003,26(5)：80.
[147]李石良,陈汉平,部慈菩,等.针刺艾灸改善NIDDM大鼠脂代谢紊乱的作用机理[J].针灸临床杂志,2000,16(1)：43-45.
[148]解秸萍,农艳,贾君君,等.针刺丰隆单穴及其配穴对高脂血症大鼠不同器官SODMDA的调配规律研究[J].2008：26(2)：262-264.
[149]农艳,解秸萍,贾君君,等.针刺丰隆单穴及其配穴对高脂血症大鼠LPLHL及肝细胞脂肪变性的效应比较[J].中华中医药学刊,2008,26(1)：82-84.
[2]吴兴斌.浅析常用调脂药物应用状况[J].临床用药,2008,5(7)：660-661.
[3]庞剑,杜文斌,周学文.高脂血症的中西医研究集析[J].中医药学刊,2003,21(12)：2124
[4]Dobiasova M, Frohieh J. The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio the lipoprotein particle size and The cholesterol esterif ication rate, changes during lipanor therapy [J]. Vnitr Lek,2000,46 (3):152-156.
[5]锦海,翟沙湖.甘油三酯/高密度脂蛋白胆固醇比值与急性冠脉综合征患者冠脉病变的关系[J].中国医药导刊,2002,4(4)：263-264.
[6]Weinberger J. Prevention of ischemic stroke [J]. Curr Card iol Rep,2002,4(2):164-171.
[7]刘晓宁,孙莉,李昭晖,等.心肌梗死和脑梗死病人载脂蛋白a五核昔酸重复序列基因多态性及血浆脂蛋白a水平的关系[J].中华医学杂志,2000,82(20)：1396-139.
[8]杨智敏.高脂血症的中医药治疗研究初探[J].现代医药卫生,2005,21(23)：3241-3242.
[9]于克娇.中医对高脂血症的认识和治疗现状[J].中国航天工业医药,2000,2(4)：79-80.
[10]周美芳.从痰瘀论治高脂血症88例临床观察[J].贵阳中医学院学报,2005,27(1)：43.
[11]李文彪,刘星,张蕴慧.高脂血症病因与发病[J].山东中医药大学学报,1999,23(5)：336-337.
[12]占新平.高脂血症中医辨证治疗的体会[J].邯郸医学高等专科学校学报,2005,8(1)：46-47.
[13]龚一萍.高脂血症的中医病因病机探讨[J].浙江中医学院学报,2000,24(2)：23-24.
[14]钱卫东,庄德成,朱学云,等.高脂血症中医病因病机探讨[J].湖北中医杂志,2001,23(11)：5-6.
[15]张琦,江泳,陈建杉.苓桂术甘汤对高脂血症大鼠血流变学影响的实验研究[J].成都中医药大学学报,2003,26(3)：11-14.
[16]范英昌,陆一竹,张艳军,等.调肝导浊中药对大鼠实验性高脂血症及主动脉平滑肌细胞增殖影响的实验研究[J].中国老年学杂志,2002,24(22)：127-129.
[17]杨大男,杨代勇,张惠芹.逍遥丸治疗高脂血症84例[J].陕西中医,1995,16(3)：109-110.
[18]吴元洁,王正,王玉凤.“痰浊”与高脂血症相关性初探[J].中医药临床杂志,2004,16(3)：201-202.
[19]从华伟,王忠玉,王玉凤.从肝脾论治高脂血症[J].中国中医药,2005,3(1)：53.
[20]尹柱汉, 陈冰.从脏腑虚实论治高脂血症[J].时珍国医国药,2001,12(6)：551.
[21]昌炳如.高脂血症的病因病机与治疗探讨[J].中医研究,2005,18(8)：3-5.
[22]浦斌红.浅谈高脂血症的中医药治疗方法[J].甘肃中医,2000,13(5)：4-6.
[23]陈志惠.高脂血症中医证治研究概述[J].福建中医药,1993,24(4)：56-59.
[24]吴卫红.调脂饮治疗高脂血症60例[J].辽宁中医杂志,2003,30(4)：279.
[25]于文涛,李进龙,田元祥,等.杨牧祥教授从痰瘀论治高脂血症的经验[J].河北中医,2006,28(3)：165-166.
[26]杜国玲.中医辨治高脂血症之经验[J].中华综合医学杂志,2005,6(7)：582.
[27]朱巧,张颖.高脂血症的中医治疗探讨[J].中国中医急症,2005,14(9)：834.
[28]岳增辉,严洁,常小荣.中医药防治高脂血症的研究进展[J].湖南中医学院学报,2005,25(2)：63-64.
[29]任合秀.试论高脂血症中医辨证思路[J].武警医学院学报,2002,11(2)：89.
[30]Grundy SM, et al. (2001). Executive summary of the third report of the National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Pane[J]. JAMA,285 (19): 2486-249.
[31]陈撷珠.实用内科学[M],第10版.北京：人民卫生出版社,1998,877-890.
[32]冯学冠,邱辅佑,黄慈花,等.379例高脂血症血脂及载脂蛋白水平的分析[J].海南医学,1994,5(1)：30-32.
[33]Wood DA. Cholesterol lowering does have a role in secondary Prevention[J].Br Heart,1995,73(1):4-5.
[34]王振杰,武阳丰,周北凡.高脂血症的膳食治疗[J].中国慢性病预防与控制,2003,11(6)：286-289.
[35]杨卫国,金莉子.膳食结构的变化对高脂血症患者血脂水平的影响[J].广西预防医学,2004,10(3)：151-153.
[36]陈玉,陈豪东.高脂血症与膳食及生活习惯的关系[J].扬州大学烹饪学报,2003,12(3)：16-18.
[37]李蓉琼,方荣华,任皓.高脂血症的非药物治疗[J].现代预防医学,2005,32(4)：324-326.
[38]Wilund K. R., Colvin PL., phares D., et al. The effect of endurance exercise training on Plasma lipoprotein Al and liPoProtein Al:All concentrations in sedentary adults[J]. Metabolism,2002,51(8):1053-1060.
[39]Sunami Y., Motoyama M., Kinoshita F., et al. Effects of low-density aerobic training on the high-density lipoprote in Cholesterol concentration in healthy elderly subjects[J]. Metabolism,1999,48(8):984-988.
[40]Kraus WE, Houmard JA, Duseha BD, et al. Effects of the amout and intensity of low intensity of exercise on Plasma lipoproteins[J]. NEngl J Med, 2002,347(19):1552-1554.
[41]Tanaka A. Diet and exercise therapy of hyperliPidemia based onevidences[J]. Nippon Rimho,2002,60(5):941-947.
[42]Prabhakaran B, Dowling EA, Branch JD, et al. Effect of 14 weeks of resistancetraining on lipid profile and body fat Percent age in premenopausal women[J]. Br J Sports Med, 1999,33(3):190-195.
[43]Halle M., Berg A., Konig D., et al. Differences in the composition of low density lipoprotein subfraction Particles between Sedentary and trained hypercholesterolemic men[J]. Metabolism,1997,46(2):186-191.
[44]Huang LP, Lu X, Lin S. Exercise of hyperlipidemia[J]. Modern Rehabilitation,2001, 5(3):10-11.
[45]郑晓辉,黄可青,佘白容,等.他汀类药物治疗高血脂的研究进展[J]. 中国误诊学杂志,2008,8(17)：4043-4044.
[46]Kong SX, Crawford SY, Gandhi SK, Seeger JD, et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of Patients with hypercholesterolemia:ameta-analysis of chlinical trials[J].Clin Ther, 1997,19(4):778-797.
[37]Downs JR, Clearfield M, Weis S, Whitney E, et al. Primary Prevention of cute coronary vents with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis prevention tudy[J]. JAMA, 1998,279(20):1615-1622.
[48]Willerson JT. Effect of pravastatin on coronary events after myocardial infarction in Patients with average cholesterol levels[J]. Circulation,1996,94(12):3054.
[49]Prevention of cardiovascular events and death with pravatatin in Patients with coronary heart disease and abroad range of initial cholesterol levels. The Long-Term ntervention with Pravastatin in Ischaemic Disease(LIPID)Study Group[J].N Eng J Med, 1998,339(19):1349-1357.
[50]Scandinavian Simvastatin Survival Study Group. Randomised trial of Cholesterol lowering in 4444 Patients with coronary heart disease:The Scandinavian Simvastatin survival study(4S) [J].Lancet,1994,344(8934):1383-1389.
[51]中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-409.
[52]陈撷珠.他汀类调脂药物[J].中国处方药,2004,27(11)：10-14.
[53]杨涛,黄斌,赵桂叶,等.氟伐他汀联合非诺贝特治疗混合性高脂血症疗效观察[J].中国实用医药,2008,3(25)：18-19.
[54]缪素琼.较大剂量阿托伐他汀钙治疗38例老年混合型高血脂症临床疗效观察[J].重庆医学,2008,37(16)：1832-1834.
[55]陆宗良.规范他汀类药物的应用[J].中国医学论坛报,2007,31(8)：14.
[56]胡大一,马长生.心脏病学实践--规范化治疗[J].北京：人民卫生出版社,2006,374.
[57]Cabrero A, Alegret M, Sanehez RM et al. Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of dipocytes[J]. Diabetes,2001,50(8):1883-1890.
[58]Marx N, Sukhova GK, Collins T et al. PPAR alpha activators inhibit cytokine-induced vascular cell adhesion Molecule-1 expression in human endothelial Cells[J]. Circulation,1999,99(24):3125-3131.
[59]Staels B, Koenig W, Habib A et al. Activation of human aortic smooth muscle cells is inhibited by PPARalpha but not by PPAR—gamma activators[J]. Nature, 1998,393(6687):790-792.
[60]赵水平,吴洁.非诺贝特对高脂血症兔血清及脂肪细胞分泌肿瘤坏死因子-α的影响[J].中国药理学通报,2005,21(2)：157-161.
[61]Rubins HB, Robins SJ, Collins D, et al, Gemfibrozil for the secondary Prevention of coronary heart disease in men with low levels of high—density lipoprotein cholesterol.Veterans AFairs High—Density Lipoprotein Cholesterol Intervention Trial Study GrouP[J].N Engl Med,1999,341(6):410—418.
[62]The BIP Study Group. Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Pations with Coronary Artery Disease[J].Cireulation,2000 Jul4, 102(1):21-27.
[63]American Diabetes Association. Management of dyslipidemia in adults with diabetes[J]. Diabetes Care,2002,25(3):574-577.
[64]Rosenberg IH. Fish-Food to Calm the Heart[J].N Engl J Med, 2002,346(15):1102-1103.
[65]Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death[J].N Engl J Med,2002,346(15):1113-1118.
[66]GISSI-Prevenzione Investgators. Dietary supplementary with n-3polyunsarated fatty aeids and vitamin E after myocardial infarction:results of the GISSI-Prevenzione trial[J]. Lancet,1999,354(9177):447-455.
[67]Hu F, Bronner L, Willett WC, et al, Fish and Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in women[J]. JAMA,2002,287(14):1815-1821.
[68]Nordoy, A; Svensson, B; Hansen, JB. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia[J]. J-Thromb-Haemost,2003,1(4):690-697.
[69]Saku K, Zhang B, Jimi S, Bai H, Hirata K, Sasaki N, et al. High-density lipoprotein and apolipoprotein Al deficiency induced by combination therapy with probucol an bezafibrate[J].EurJClinPharmaeol,1995,48(3-4):209-215.
[70]Chiesa G, Miehelagnoli S, Cassinotti M, Gianfraneesehi G, Werba JP, Pazzueeoni F, et al. Meehanisms of high density lipoprotein reduction after probucol treatment: changes in plasma cholesterol esterification/transfer and lipase activitie[J]. Metabolism,1993,42(2):229-23.
[71]Homma Y, Kobayashi T, Yamaguchi H, Sakane H, Ozawa H, Matsuda M, et al. Decrease of plasma large, light LDL(LDL1), HDL2 and HDL3 levels with concomitant inerease of cholesteryl eater transfer protein(CETP) activity by Probueol in typeⅡ hyperlipoproteinemia[J]. Artery,1993,20(1):1-18.
[72]Sawayama,-Y, Shimizu,-C, Maeda,-N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial(FAST) [J]. J-Am-Coll-Cardiol,2002,39(4):610-616.
[73]Gagne ac, Gaudet D, Bruekert E, et al. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in pations with homozygous familial hypercholesterolemia[J]. Circulation,2002,105(21):2469-2475.
[74]华琦,师树英,王亭,等.苯氧芳酸类血脂调节药物吉非罗齐疗效观察[J].中华内科杂志,1997,36(11)：735.
[75]任景怡,陈红,罗宇.联合应用辛伐他汀和非诺贝特治疗混合性高脂血症的疗效及安全性观察[J].中华心血管病杂志,2005,33(2)：122-126.
[76]Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate(200mg/day) to simvastatin(10mg/day) in Patients with combined hyPerliPidemia and metabolic syndrome[J]. Am J cardiol,2003,91(8):956-960.
[77]Hodel C. MyoPathy and rhabdomyolysis with lipid-lowering drugs[J]. Toxicol Lett,2002,128(1-3):159-168.
[78]Snow V, Aronson MD, Hornbak ER, et al. Lipid control in the management of type 2 diabetes mellitus:a clinical practice guide line from the American College of Physicians[J]. Ann Intern Med,2004,140(8):644-649.
[79]American diabetes association. DysliPidemia management in adults with diabetes[J]. Diabetes Care.2004,27 SuPPll:568-571.
[80]Brown BG Zhao X-Q, Chain A et al. Simvastatin and niacin, antioxidant vitamin, or the combination for the Prevention of coronary disease[J]. N Engl J Med,2001,345(22):1583-1592.
[81]Jokubaitis LA. Fluvastatin in combination with other lipid lowering agents[J].Br J Clin Prcet Suppl,1996,77A:28-32.
[82]Erkelens DW, Baggen MG, Van Doormaal J J, et al. Clinical experience with Simvastatin compared with cholestyramine[J]. Drugs,1988,36 suppl 3:87-92.
[83]Durrington,-P-N,Bhatnaga,-D, Mackness,-M-I, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and Persisting hypertriglyceridaemia[J]. Heart,2001,85 (5):544-548.
[84]Tadateru T, Aggressive Lipid-Lowering Therapy for Secondary prevention in pations with Acute Coronary Syndrome:Volumetric and Echogenicity Analysis Using Intravascular Ultrasound. Presented on 68 th seientific Sessions of Japanese Circulation Society. March 2-29,2004. Tokyo, Japan Plenary Sessionl.
[85]张莉.中医药治疗高脂血症研究进展与展望[J].河北中医,2007,29(4)：376-377.
[86]宋立人.现代中药学大辞典[M].北京：人民卫生出版社,2001,790.
[87]王宇辉,周超凡.中药降脂研究进展[J].中国中药杂志,1999,24(3)：184-186.
[88]蔡永敏.最新中药药理与临床应用[M].北京：华夏出版社,1999,54-481.
[89]焦东海.大黄糖浆降脂作用的临床观察[J].中西医结合杂志,1990,10(2)：110-111.
[90]柴跃红,窦敏华,窦翠华.何首乌治疗高脂血症36例疗效观察[J].河北中医,2000,22(5)：346.
[91]梅齐建,吴仁如,肖鸣.抗栓灵含片对老年人高脂血和血液流变学的影响[J].中国生化药物杂志,2000,21(5)：452.
[92]詹丽芬,孙晋民,孙立,等.轻身降脂片对高血脂大鼠丙二醛及超氧化物歧化酶的影响[J].中国医科大学学报,2000,29(3)：341.
[93]王四旺,谢艳华,朱玲珍.平脂胶囊对鼠血脂和血粘的影响[J].第四军医大学学报,1999,20(10)：345.
[94]李春梅,刘莉.降脂通脉冲剂对实验性高脂血症大鼠血浆脂质及血粘度的影响[J].山西医科大学学报,2000,31(1)：34.
[95]张吉正,范英昌,张伯礼,等.脂肝清对高胆固醇血症家兔模型脂质代谢影响的实验研究[J].天津中医,2000,18(6)：29.
[96]左绍远.复方螺旋藻片降血糖、调血脂的实验研究[J].中国海洋药物,2000,19(6)：679.
[97]于志强.中医药治疗高脂血症六法[J].辽宁中医学院学报,2000,2(2)：119.
[98]吴同启.从肝脾论治高脂血症60例[J].陕西中医,2004,25(2)：133-134.
[99]王化锰.以痰凝为核心治疗高脂血症46例[J].辽宁中医杂志,2000,27(11)：499.
[100]刘启明.燥湿化痰、消积降脂法治疗高脂血症93例[J].中医药学报,2001,29(2)：9.
[101]姜文良,郭茂峰.中西医结合治疗高脂血症73例疗效观察[J].河南中医,2005,5(10)：64.
[102]钱卫东,朱学云.高脂血症中医辨治体会[J].江苏中医,2000,21(12)：14.
[103]王兴国,杜洪柱,刘华光.辨证分型治疗高脂血症102例观[J].实用中医药杂志,1999,15(9)：3-4.
[104]尹修海,罗永铁.辩证分型治疗高脂血症120例分析[J].湖南中医杂志,1999,15(3)：8-9.
[105]胡克武,丁俊.肝肾阴虚型高脂血症治疗的临床分析[J].辽宁中医杂志,1996,23(12)：542-543.
[106]马洪玲.逍遥散加减治疗高脂血症50例[J].山东中医杂志,2001,20(7)：402.
[107]谭元生,程丑夫,黄大香,等.脂康颗粒剂治疗肝肾阴虚夹癖型高脂血症的临床研究[J].中国中医药科技,1999,6(4)：213-214.
[108]袁俏梅,史红辉.穴位埋线治疗高脂血症34例—附普拉固治疗30例对照[J].浙江中医杂志,2002,23(6)：396.
[109]朱雅萍.电针治疗高脂血症60例[J].吉林中医药,2001,4(10)：53.
[110]赵惠.针刺辨证选穴治疗高脂血症的临床研究[J].中国初级卫生保健,2002,16(10)：54-55.
[111]任敬威.针刺足三里、内关穴治疗高脂血症45例报告[J].甘肃中医,1996,9(8)：36-37.
[112]毛豆菜,王月冬,周逸平.针刺对冠心病患者血脂血糖的影响[J].针灸临床杂志,1994,10(2)：26-27.
[113]周杰芳,冼志红.针刺对高血脂病人的血脂及血液流变学影响的临床观察[J].广西中医药,1994,17(3)：39-41.
[114]粱凤应.针灸对老年人高脂血症及高粘血症的影响[J].上海针灸杂志,1999,18(4)：10-12.
[115]张红星,张唐法,周利,等.电针丰隆穴治疗高脂血症临床研究[J].针灸临床杂志,2007,23(4)：7.
[116]李春杰,成小松,李春艳,等.针刺丰隆穴对正常和高脂血症大鼠血脂的调节作用[J].中国临床康复,2005,9(27)：86-87.
[117]王玉堂.针刺丰隆穴降血脂47例临床观察[J].中国针灸,1990,10(3)：21.
[118]陈德欣,吴洪英,王卓茹.针刺阳明经穴治疗高脂血症疗效观察[J].针灸临床杂志,2002,18(5)：49.
[119]陈瑞,梁风霞,毛红蓉.针刺从脾论治高脂血症的临床研究[J].中国中西医结合消化杂志,2003,11(3)：162-164.
[120]于连群.补脾泻胃针刺法治疗高脂血症疗效观察[J].中华现代中西医杂志,2005,3(11)：1027.
[121]唐胜修,唐萍.丰隆、足三里穴位注射治疗高脂血症的临床研究[J].广西医学杂志,2000,22(6)：1402.
[122]冷浩.高脂血症的针灸治疗临床观察[J].光明中医,2007,22(2)：33.
[123]张苹.针灸治疗高脂血症的临床资料分析[J].中外医疗,2008,14：6-7.
[124]刘红石.针刺并降脂减肥茶治疗单纯性肥胖并高脂蛋白血症20例[J].针灸临床杂志,2004,20(4)：17-18.
[125]曾奕.艾灸作用的实验研究进展[J].山东中医杂志,2005,24(3)：187-190.
[126]高耀华,王竹行,陈新黔,等.降脂药灸治疗中老年高脂血症的临床研究[J].中国针灸,2000,20(2)：77.
[127]史恒军,赵宁侠,郭瑞林,等.温和灸对健康人甲皱微循环影响的临床研究[J].成都中医药大学学报,2004,27(1)：42-43.
[128]邓柏颖,谢感共,罗本华,等.功能保健灸治疗高脂血症48例疗效观察[J].新中医,2002,34(9)：48-49.
[129]管遵惠,金建华,申晓月.子午流注灸法治疗高脂血症50例临床观察[J]. 中医杂志,1994,35(2)：108-109.
[130]吴中朝,王玲玲,刘跃光,等.艾灸对老年人血液载脂蛋白研究[J].中国针灸,1998,18(5)：261-262.
[131]李建萍,姚永年,何培达,等.艾灸治疗血脂异常患者的临床研究[J].中国针灸,2005,25(11)：825-827.
[132]张红星,张唐法,周利等.电针丰隆穴治疗高脂血症临床研究[J].针灸临床杂志,2007,23(4)：7-8.
[133]卢振初.耳压法治疗单纯性肥胖症29例的血脂和脂蛋白观察[J].南京中医学院学报,1989,(2)：40.
[134]王华.丹参穴位注射治疗高脂血症40例临床分析[J].中国针灸,1997,(8)：469.
[135]刘晓辉.当归维生素B12混合穴位注射治疗高脂血症56例[J].时珍国医国药,2001,12(4)：360.
[136]刘运珠,岁继红,宁发锦,等.穴位注射对高脂血症患者血脂的影响[J].上海针灸杂志,2007；26(2)：15-16.
[137]王倩,熊萃,等.穴位埋线治疗肥胖型高脂血症52例疗效观察[J].新中医,2005,37(6)：64-65.
[138]李兴文.He-Ne激光穴位照射治疗高脂血症疗效观察[J].中国临床医学,2000,7(3)：317.
[139]李相忠,董壮丽.超声波治疗高脂血症的实验及临床观察[J].中国循环杂志,1994;9(8)：46.
[140]王成传,郑建寅,谢宁.哈慈五行针治疗飞行人员高脂血症疗效观察[J].中华航空航天医学杂志,2001,12(4)：239-240.
[141]张丽,盛丽.磁化针治疗高脂血症的疗效观察[J].中国针灸,2002,22(5)：337-338.
[142]杨国柱,曹欣.皮内针治疗高脂血症32例临床观察[J].江苏中医药,2003,24(12)：38.
[143]包哈申,斯钦图,那顺布和,等.放血疗法治疗高脂血症的临床观察[J].针灸临床杂志,2002,18(11)：33-35.
[144]韩丽英.穴位贴敷治疗高脂血症临床观察[J].辽宁中医杂志,2003,30(6)：462
[145]杨丹红,许文波,江庆湛.穴位注射对高脂血症动物模型的降脂作用[J].针灸临床杂志,2000,16(1)：43-45.
[146]解秸萍,李晓乱,张露芬,等.针刺不同穴位对高脂血症大鼠血脂影响的实验研究[J].北京中医药大学学报,2003,26(5)：80.
[147]李石良,陈汉平,部慈菩,等.针刺艾灸改善NIDDM大鼠脂代谢紊乱的作用机理[J].针灸临床杂志,2000,16(1)：43-45.
[148]解秸萍,农艳,贾君君,等.针刺丰隆单穴及其配穴对高脂血症大鼠不同器官SODMDA的调配规律研究[J].2008：26(2)：262-264.
[149]农艳,解秸萍,贾君君,等.针刺丰隆单穴及其配穴对高脂血症大鼠LPLHL及肝细胞脂肪变性的效应比较[J].中华中医药学刊,2008,26(1)：82-84.